Intermediatepublic finance
Healthcare Economics: Why Markets Struggle With Health
Overview
Healthcare defies normal markets: patients can't judge what they need (doctors decide), insurance invites overuse (moral hazard) and unravels without mandates (adverse selection), and societies won't let people die for lack of money. Every rich country intervenes massively — yet designs differ radically (US, UK, Germany, Singapore). This lesson explains health's market failures, the insurance core, the big system models, and what the evidence says works.
Learning objectives
- Explain health's unique market failures
- Analyze moral hazard and adverse selection in health insurance
- Compare system models: NHS, Bismarck, single-payer, market-based
- Evaluate the US system's costs and gaps
- Assess what drives health spending and how to control it
Why health isn't like other markets
Four features break textbook markets. Uncertainty: illness is unpredictable — insurance is essential, but creates its own problems. Asymmetric information: doctors know more than patients (supplier-induced demand — physicians can generate their own business); insurers know less than the sick (adverse selection). Externalities: vaccinations and infectious-disease control benefit others — markets underprovide. And the Samaritan's dilemma: societies won't deny emergency care, so the uninsured free-ride — mandating coverage or providing it publicly follows. Kenneth Arrow (1963) founded the field by showing these features make health uniquely market-failure-prone.
The founding paper: uncertainty and asymmetric information pervade health care, making competitive markets systematically fail — the intellectual charter for health intervention everywhere.
Moral hazard and adverse selection
Moral hazard: insurance lowers the price of care to near-zero, so people consume more (and providers supply more) — the RAND Health Insurance Experiment quantified it: free care raised spending ~40% with little average health gain. Cost-sharing (deductibles, copays) controls it but deters needed care too — blunt instrument. Adverse selection: the sick buy insurance eagerly, the healthy skip it — premiums spiral (the 'death spiral') unless mandates or subsidies keep the healthy in. The ACA's individual mandate and subsidies were adverse-selection engineering. Every insurance design trades these two: cost-sharing fights moral hazard but worsens selection; generosity reverses both.
The landmark 1970s RCT: randomly assigned insurance generosity. Free care → ~40% more spending, minimal average health effects (the poor and sick benefited some). Still the best evidence on moral hazard in health.
Four system models
NHS/Beveridge (UK, Nordics): tax-funded, government-provided — universal, cheap (~11% of GDP), but with waiting lists and rationing by queue. Bismarck (Germany, France, Japan): mandated non-profit insurers ('sickness funds'), private providers — universal, expensive-ish (~12–13%), choice preserved. Single-payer/NHI (Canada, Taiwan): government insurance, private delivery — universal, administrative simplicity, with wait-time politics. Market-based (US): employer insurance + public programs + uninsured — most expensive (~17–18% of GDP), best-funded top end, worst access gaps. No model dominates all dimensions — each rations differently: by price (US), queue (UK/Canada), or benefits package (everywhere, quietly).
The US rations by price and insurance; others by waiting and benefit design. 'No rationing' isn't an option — the honest debate is which rationing is fairest.
The US puzzle: spending without health
America spends ~17–18% of GDP on health — roughly double peer nations — for worse population health (lower life expectancy, higher infant mortality). Why? Prices, not quantities: US drugs, procedures, and salaries cost far more (the 'it's the prices, stupid' finding — Anderson et al.). Administrative waste: hundreds of insurers mean ~15–25% overhead vs. ~2–5% in single-payer systems. Fragmentation: uncoordinated care, defensive medicine, and profit-maximizing consolidation. And 25+ million uninsured (pre-ACA more) — access gaps amid plenty. The US doesn't over-consume care; it overpays for it. Price regulation and administrative simplification are the evidence-backed fixes — not more consumer cost-sharing.
Cross-country, the US uses roughly average amounts of care (fewer doctor visits than peers!) but pays far higher prices. Spending control means price control, whatever the system design.
Controlling spending: what works
Global budgets (hospitals get fixed sums — Maryland, much of Europe): hard caps that work. Price regulation (fee schedules — Germany, Japan): administrative pricing beats market bargaining. Primary-care gatekeeping: coordination cuts duplication. Health technology assessment (NICE in the UK): cost-per-QALY thresholds for coverage — explicit rationing by value. Payment reform: capitation and bundled payments align provider incentives (fee-for-service rewards volume). Prevention's limits: it improves health but rarely saves money (screening costs too). The meta-lesson: every successful system constrains prices or quantities administratively — markets alone have never controlled health spending anywhere.
Key points
- Health markets fail uniquely: uncertainty, asymmetric information (both directions), externalities, and the Samaritan's dilemma (Arrow 1963).
- Insurance trades moral hazard (overuse — RAND: +40% spending) against adverse selection (death spirals) — mandates and subsidies manage the latter.
- Four models — NHS, Bismarck, single-payer, US market-based — ration differently: by queue, benefits, or price.
- The US spends ~2x peers for worse health because of prices and administration, not quantities of care.
- Spending control that works: global budgets, fee schedules, HTA (NICE), and payment reform — administrative constraint, everywhere.
Common misconceptions
✓ Truth: No country has achieved low-cost universal care through unregulated markets — health's information failures are too deep. Every efficient system uses heavy administration of prices or budgets.
✓ Truth: The best-funded top end, yes — but population health trails peers badly, tens of millions face access gaps, and medical bills are the leading cause of bankruptcy. Excellence for some, system failure overall.
✓ Truth: Prevention improves health and is often worth it — but most preventive care costs more than it saves (screening the healthy is expensive). It's a health investment, not a budget fix.
Practice questions
Q1. Arrow's (1963) foundational claim was that healthcare markets fail systematically because of:
- Too much competition
- Pervasive uncertainty and asymmetric information — patients can't judge needs, insurers can't judge risks
- Low demand
- Excessive government
Uncertainty plus two-sided information asymmetry (doctors know more than patients; patients know more than insurers) makes competitive health markets fail — the charter for universal intervention.
Q2. The RAND Health Insurance Experiment's central finding was:
- Insurance is unnecessary
- Free care raised spending ~40% (moral hazard) with little average health gain — though the poor and sick benefited
- Copays don't matter
- Everyone overuses emergency rooms
Cost-sharing powerfully controls spending (moral hazard is real) but the health effects were small on average — the core tradeoff in insurance design, from the best RCT ever run on it.
Q3. The main reason the US spends ~2x peer nations on health is:
- Americans use far more care
- Higher prices for drugs, procedures, and administration — the US uses average quantities but pays far more per unit
- An older population
- More hospitals
'It's the prices, stupid': fewer doctor visits than peers, but dramatically higher unit prices plus multi-payer administrative overhead. Spending control means price control.
Click a question to reveal the answer and explanation.
Frequently asked questions
What is a QALY?
Quality-adjusted life year — one year in perfect health. Cost-per-QALY thresholds (e.g., UK NICE's ~£20–30k) let systems compare treatments' value explicitly — rationing by cost-effectiveness.
Why do US drug prices exceed other countries'?
Other countries negotiate or regulate prices; the US largely doesn't (Medicare was barred from negotiating until recently). Pharma charges what each market bears — Americans bear the most.
What is supplier-induced demand?
Physicians influencing patients to consume more care than informed patients would choose — possible because of information asymmetry, amplified by fee-for-service payment. Gatekeeping and capitation counter it.
How does Singapore do it?
Mandatory health savings (Medisave), catastrophic insurance, and heavy government price regulation — individual responsibility rhetoric atop tight state control of prices and supply. Often misdescribed as market-based.